3D Medicines (Sichuan) Co.Ltd.
Envafolimab(3D Medicines (Sichuan) Co., Ltd.)은 Prostate Cancer 표적 항체로, Prostate Cancer; CDK12 Gene Mutation 영역에서 개발·상용화 중입니다. 작용기전: of envafolimab (also known as KN035), a programmed death ligand 1 (PD-L1) inhibitor, in gastric adenocarcinoma patients with low PD-L1 expression is not well understood. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 52건의 관련 임상이 등록되어 있습니다. 차별점: novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
Prostate Cancer
Prostate Cancer; CDK12 Gene Mutation
Recruiting
ADC)] and envafolimab (a programmed death-ligand 1 inhibitor)
humanized single-domain PD-L1 antibody and human IgG1 Fc fragment formulated for subcutaneous injection
novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors
of envafolimab (also known as KN035), a programmed death ligand 1 (PD-L1) inhibitor, in gastric adenocarcinoma patients with low PD-L1 expression is not well understood
T-cell activation
apoptosis of gastric cancer cells was detected by flow cytometry
PD-L1)-positive
Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
3D Medicines (Sichuan) Co.Ltd.
Envafolimab(3D Medicines (Sichuan) Co., Ltd.)은 Prostate Cancer 표적 항체로, Prostate Cancer; CDK12 Gene Mutation 영역에서 개발·상용화 중입니다. 작용기전: of envafolimab (also known as KN035), a programmed death ligand 1 (PD-L1) inhibitor, in gastric adenocarcinoma patients with low PD-L1 expression is not well understood. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 52건의 관련 임상이 등록되어 있습니다. 차별점: novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
Prostate Cancer
Prostate Cancer; CDK12 Gene Mutation
Recruiting
ADC)] and envafolimab (a programmed death-ligand 1 inhibitor)
humanized single-domain PD-L1 antibody and human IgG1 Fc fragment formulated for subcutaneous injection
novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors
of envafolimab (also known as KN035), a programmed death ligand 1 (PD-L1) inhibitor, in gastric adenocarcinoma patients with low PD-L1 expression is not well understood
T-cell activation
apoptosis of gastric cancer cells was detected by flow cytometry
PD-L1)-positive
Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.